Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morphomer alpha-syn
- Development stage
- Preclinical
- Lead developer
- AC Immune
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Morphomer alpha-syn is a small molecule alpha-synuclein aggregation inhibitor being developed by AC Immune for the treatment of Parkinson's disease and other alpha-synucleinopathies. Derived from AC Immune's proprietary Morphomer discovery platform, the compound is designed to prevent the intracellular aggregation and spreading of pathological alpha-synuclein, which is a key driver of neurodegeneration in Parkinson's disease. The program has received grant funding from The Michael J. Fox Foundation for Parkinson's Research and is currently in the discovery and preclinical development stages.
- Other names
- Morphomer a-syn
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))
Beyond the preview
Go deeper on Morphomer alpha-syn.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Morphomer alpha-syn.